Here's What Key Metrics Tell Us About Aquestive Therapeutics (AQST) Q3 Earnings

Core Insights - Aquestive Therapeutics reported a revenue of $12.81 million for the quarter ended September 2025, reflecting a decrease of 5.4% year-over-year and a revenue surprise of -4.13% compared to the Zacks Consensus Estimate of $13.36 million [1] - The company's EPS was -$0.14, slightly worse than the -$0.13 EPS from the same quarter last year, resulting in an EPS surprise of -7.69% against the consensus estimate [1] Revenue Breakdown - Manufacture and supply revenue was reported at $11.47 million, exceeding the average estimate of $10.48 million by four analysts, and showing a year-over-year increase of 7.5% [4] - Co-development and research fees amounted to $0.3 million, falling short of the three-analyst average estimate of $0.53 million, representing a significant year-over-year decline of 38.6% [4] - License and royalty revenue was reported at $1.04 million, which is below the three-analyst average estimate of $2.3 million, indicating a year-over-year decrease of 52% [4] Stock Performance - Over the past month, shares of Aquestive Therapeutics have returned +1.8%, outperforming the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance in the near term [3]